by Jordyn Sava
With encouraging response rates and a well-tolerated safety profile seen in RAMP-201, experts are hopeful for the accelerated approval of avutometinib plus defactinib for low-grade serous ovarian cancer.
The combination of avutometinib (VS-6766) with defactinib (VS-6063), as … Read more
by Brielle Benyon
Tafinlar plus Mekinist is now approved by the Food and Drug Administration to treat adults and children over the age of 6 who have BRAF V600-mutant advanced solid cancers.
The Food and Drug Administration (FDA) approved Tafinlar
by Rachel N. Grisham, M.D.
As summarized in this issue of The ASCO Post, the highly anticipated results of the GOG 281/LOGS study, which randomly assigned patients with recurrent low-grade serous ovarian cancer to the MEK inhibitor trametinib vs … Read more
A new combination of targeted drugs for a type of ovarian cancer has shown promising results in an early clinical trial – shrinking tumours in half of patients.
The combination of drugs – which both work by blocking signals cancer … Read more
By Ian Ingram
For women with recurrent or persistent low-grade serous ovarian cancer (LGSOC), presence of a KRAS mutation appeared to predict benefit from binimetinib (Mektovi), a post-hoc analysis from the phase III MILO trial found.
Among women treated with … Read more
By Denise Myshko
Trametinib (Mekinist) monotherapy has emerged as a new treatment option for women with recurrent low-grade serous ovarian cancers based on improvements in survival outcomes and response rates demonstrated in a phase II/III study, according to David M. … Read more
By Pam Harrison
Targeted drug provokes good response in chemoresistant, low-grade serous ovarian or peritoneal cancer.
Trametinib (Mekinist) treatment was associated with better outcomes in women with recurrent or progressive low-grade serous ovarian or peritoneal cancer versus treatment with standard-of-care … Read more
